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BACKGROUND: The type I insulin-like growth factor receptor (IGF1R) is a transmembrane tyrosine kinase involved in cancer
proliferation, survival, and metastasis.
METHODS: In this study, we used two different fluorescent technologies (small-molecule fluorophores and quantum dot (QD)
nanoparticles) to detect receptor expression and its downregulation by antibodies in vivo.
RESULTS: After conjugation with AVE-1642, a humanised anti-IGF1R monoclonal antibody, both QDs (705nm) or Alexa 680 (small-
molecule fluorophore) detected expression and downregulation of IGF1R in vitro. To examine their utility in vivo, either AVE-1642
conjugates were intravenously delivered to mice bearing xenograft tumours of mouse embryo fibroblasts expressing human IGF1R or
MCF-7 human breast cancer cells. Quantum dot fluorescence was mainly localised to the reticuloendothelial system in several organs
and engulfed by macrophages, with only very small amount of QDs detected in the xenograft tumours. Depletion of macrophages by
clodronate liposomes did not alter the nonspecific uptake of QDs. In contrast, AVE-1642-conjugated Alexa 680 solely targeted to
xenograft tumour and was able to detect IGF1R downregulation, with little nonspecific targeting to other tissues or organs in mice.
CONCLUSION: Taken together, our data suggest that small-molecule fluorophores, not QDs, are suitable to detect the expression and
downregulation of IGF1R in vivo.
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In recent years, targeted therapies against specific membrane
proteins have been developed as cancer treatments. One critical
question in the development of this new class of drugs is to
determine the expression of the target in vivo. Therapeutic benefit
may be linked to the expression level of the molecular targets in
the primary tumour site. For example, trastuzumab, the anti-HER2
antibody, is most effective in tumours overexpressing HER-2
(Nahta and Esteva, 2003). Therefore, the accurate assessment of
HER-2 expression levels is essential for HER-2-targeted therapy.
Certainly, the presence of the target is a necessary requirement for
response to this type of drug.
The type I insulin-like growth factor receptor (IGF1R) is a
receptor tyrosine kinase that plays critical roles in cancer
progression and metastasis. Overexpression and activation of
IGF1R has been reported in many types of cancer (Zhang and Yee,
2004, 2006). In the past few years, monoclonal antibodies and
tyrosine kinase inhibitors have been developed to target IGF1R
(Sachdev and Yee, 2006). Several anti-IGF1R monoclonal anti-
bodies are in phase I, II, and III clinical trials. One interesting
common feature about the antibodies is their ability to bind and
downregulate IGF1R level through receptor-mediated endocytosis.
Downregulation of IGF1R was associated with decreased tumour
growth in xenograft tumour models (Burtrum et al, 2003; Maloney
et al, 2003; Goetsch et al, 2005). Therefore, IGF1R downregulation
could be used as a biodynamic marker of antibody delivery and a
potential indicator of response.
In current anti-IGF1R clinical trials, patient enrolment is not
based on the expression of IGF1R in the primary tumour.
Although IGF1R is necessary for response to anti-IGF1R therapies,
it is uncertain whether there is a relationship between patient
response and levels of IGF1R expression in the tumour. Preclinical
studies from Sanofi-aventis (Paris, France) have shown that there
is no direct correlation between the antiproliferative effect of a
human anti-IGF1R antibody, AVE-1642, and the level of IGF1R in
more than 90 tumour cell lines (data not shown). Unlike HER-2,
where expression levels are routinely measured by fluorescent in
situ hybridisation or immunohistochemistry in clinical settings, a
technique to quantitatively measure IGF1R level in tumour
specimens has not yet been subjected to rigorous study. Moreover,
there have not been reliable ways to measure receptor expression
level in vivo. Recently, our laboratory has shown that anti-IGF1R
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santibody, which is specific for human IGF1R, when conjugated
with quantum dots (QDs), has the ability to measure IGF1R level
quantitatively (Zhang et al, 2008a).
Quantum dots are nanocrystals that emit fluorescence upon
excitation. Compared with other types of fluorophore, QDs have
high brightness and photostability (Zhang et al, 2008b). The
recently developed cadmium telluride (Cd/Te) QDs emit fluores-
cence in the red and near-infrared range, which is ideal for in vivo
imaging to avoid tissue auto-fluorescence. In fact, it has been
applied to map sentinel lymph nodes in animal cancer models
(Kim et al, 2004; Parungo et al, 2005; Soltesz et al, 2005, 2006;
Hama et al, 2007; Knapp et al, 2007).
Although we have shown that AVE-1642-conjugated QDs are
excellent agents to measure IGF1R level in cell lines with high
specificity, their in vivo properties had not been investigated. As
breast cancer metastasises to distant organs, it is often not
clinically feasible to biopsy these tissues and measure levels of
IGF1R in those sites. There is little evidence of gene amplification
of IGF1R in breast cancer (Berns et al, 1992), and the level of
IGF1R could vary from the primary tumour to metastatic tumours.
Therefore, it is necessary to develop non-invasive in vivo imaging
technology to quantitatively measure IGF1R levels in metastasised
tumours and to be able to track the pharmacodynamic activity of
antibody therapy.
In this study, the IGF1R-specific antibody, AVE-1642, was
conjugated to Cd/Te QDs (with a peak emission at 705nm). As a
direct comparison, a small-molecule fluorophore, Alexa 680, with
the same peak emission at 705nm, was covalently linked to AVE-
1642. We show that both antibody-conjugated Alexa 680, and QDs,
localised to xenograft tumours that express IGF1R. However, QD
localisation to the tumour was nonspecific and independent of
antibody conjugation. Moreover, QDs were nonspecifically located
in liver sinusoids. In contrast, only Alexa 680 fluorescence in
tumour was dependent on IGF1R expression. Our results suggest
that small-molecule fluorophores, such as Alexa 680, are more
suitable for in vivo tumour imaging to identify IGF1R expression
and its downregulation.
MATERIALS AND METHODS
Reagents
All chemical reagents were purchased from Sigma (St Louis, MO,
USA) unless otherwise indicated. Optimum cutting temperature
(OCT) compound was purchased from Sakura (San Marcos, CA,
USA). AVE-1642 was developed by Sanofi-aventis and anti-CD20
antibody was a gift from ImmunoGen (Cambridge, MA, USA). The
rat anti-mouse MOMA-2 antibody was purchased from AbD
Serotec (Raleigh, NC, USA). SlowFade Gold antifade reagent with
DAPI, goat anti-mouse Alexa Fluor 488, Qdot antibody conjuga-
tion kit, and the SAIVI rapid antibody labelling kit were purchased
from Invitrogen (Carlsbad, CA, USA).
Cell lines and culture
R cells (mouse fibroblast cells with a homozygous disruption of
IGF1R gene) and R-/IGF1R cells (cell line derived from R cells with
re-introduced IGF1R gene) were cultured according to literature
(Sachdev et al, 2006). R cells were a gift from Renato Baserga
(Thomas Jefferson University, Philadelphia, PA, USA) (Steller et al,
1996; Sachdev et al, 2006). MCF-7 cells were cultured in Dulbecco’s
modified Eagle’s medium with 10% foetal bovine serum.
Conjugation of antibody with QD 705nm
AVE-1642 was conjugated to Cd/Te QDs (emission at 705nm)
through a heterobifunctional cross-linker, succinimidyl-4-(N-
maleimidomethyl) cyclohexane-1-carboxylate (SMCC). The NHS
ester end of SMCC reacted with the amine groups on the Cd/Te
QDs, and the maleimide end of SMCC coupled to the sulfhydryls
on the DTT-reduced antibody according to the instructions of the
manufacturer (Invitrogen). Conjugate concentration was deter-
mined by the absorbance measured at 550nm and was calculated
using the extinction coefficient (1700000 M
 1cm
 1).
Conjugation of antibody with Alexa 680
AVE-1642 was conjugated to Alexa 680 using the SAIVI rapid
antibody labelling kit from Invitrogen. The conjugate was purified
by size exclusion column and its concentration was determined by
the absorbance measured at 679nm and calculated using the
extinction coefficient (180000 M
 1cm
 1).
Size exclusion chromatography
Gel filtration samples were fractionated with a Superdex G200
size exclusion column (GE Healthcare, Pittsburgh, PA, USA), eluted
with P500 buffer (0.5 M NaCl, 50mM KH2PO4,1m M EDTA, pH 7.0),
and the relative peak retention time quantified by absorbance at
280nm. The Superdex G200 column was calibrated with a
molecular weight standards kit (Sigma). The test reagents were
blue dextran (MW¼2000kDa), thyroglobulin (669kDa), apo-
ferritin (443kDa), b-amylase (200kDa), alcohol dehydrogenase
(150kDa), bovine serum albumin (66kDa), and carbonic an-
hydrase (29kDa).
Flow cytometry
Cells were trypsinised and resuspended in PBS/1% BSA/0.1%
sodium azide (FACS buffer). Cells were incubated with free or
conjugated QDs or Alexa 680 in FACS buffer for 1h at 41C. Cells
were washed twice and resuspended with 400ml FACS buffer.
IGF1R levels on cell surface were measured using an LSRII flow
cytometer (BD Biosciences, San Jose, CA, USA). Quantum dot
705nm fluorescence was obtained with a band filter at 700/40nm
using an excitation laser at violet. Alexa 680 fluorescence was
obtained with a band filter at 700/40nm using an excitation laser at
633nm.
Tumour growth in athymic mice and delivery of
antibody-conjugated fluorophores
All animal studies were performed under the guideline of a
university-approved animal care and use protocol (protocol no.
0511A77590 and renewed protocol no. 0807A40961). Female
athymic mice, 4–5 weeks old (Foxn1nu strain from Harlan
Sprague Dawley, Indianapolis, IN, USA), were injected in the
second or seventh mammary fat pad with 5 10
6 R-/IGF1R cells or
MCF-7 cells. For mice injected with MCF-7 cells, mice also were
implanted with a slow-release capsule of 17-b oestradiol (Sigma)
subcutaneously in the dorsal neck region 1 day before the cell
injection. When tumour volume reached 100–300mm
3, approxi-
mately 0.1nmol of antibody-conjugated Alexa 680 or QDs (at
about 200ml volume) was injected intravenously into the tail vein
of mice. For antibody pretreatment experiment, 200mg of AVE-
1642 was injected into mice intraperitoneally.
Clodronate liposome preparation and delivery into mice
Clodronate liposome or the PBS liposome was prepared according
to literature (Van Rooijen and Sanders, 1994). About 200mlo f
clodronate liposome or PBS liposome was administered into mice
through tail vein injection.
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Right before imaging, mice were anaesthetised in a closed chamber
with isoflurane gas (administered in conjunction with pure
oxygen). Then mice were quickly translocated into the imaging
chamber of the Maestro in vivo fluorescence imaging system (CRI,
Woburn, MA, USA). The heads of mice were inserted into the nose
cone with continuous isoflurane gas flow to keep them anaes-
thetised during the imaging process. Fluorescence was excited with
an excitation filter at 575–605nm and images were captured at the
645–850nm range in 10nm steps with an emission filter 645LP.
Raw, mixed signal images were analysed by the Maestro 2.2
software to isolate the autofluorescence (based on the control
animal) and QD (or Alexa 680) fluorescence.
Tumour ex vivo imaging
Xenograft tumours were removed from the surrounding tissue
soon after mice were killed by CO2 overdose. Tumours were cut
open and placed in the imaging chamber, and tumour fluorescence
was captured by the Maestro in vivo imaging system and analysed
by the Maestro 2.2 software.
Liver sample preparation
Liver specimens were taken right after mice were killed by CO2
overdose and frozen using the OCT compound in liquid nitrogen.
Liver samples were sectioned at 8mm thickness.
Toluidine blue staining
After fixation with acetone, liver sections were placed in distilled
water for 1min and then into a 1% toluidine blue O solution, pH
5.5, for 1min. Finally, slides were mounted with SlowFade Gold
antifade reagent.
Immunofluorescent staining
After blocking in casein block solution, liver sections were
incubated with rabbit anti-mouse MOMA-2 antibody (1:25). The
41C overnight primary incubation was followed by secondary
applications with goat anti-mouse Alexa Fluor 488 (1:250). Finally,
slides were mounted with SlowFade Gold antifade reagent with
DAPI.
Confocal microscopy
Confocal laser scanning microscopy was performed with an
Olympus Fluoview FV500 laser scanning confocal system
(Olympus, Center Valley, PA, USA), using a  60 oil immersion
objective. Excitation lasers and filters were as follows: DAPI, blue
diode laser, emission 430–460nm; MOMA-2, argon laser, emission
505–525nm; Alexa 680, red He–Ne laser, emission LP 660nm; and
QD 705nm, blue diode laser, emission LP 660nm.
RESULTS
Molecular weights of QDs and Alexa 680 conjugates
measured by size exclusion chromatography
The IGF1R-specific antibody, AVE-1642, was conjugated to the Cd/
Te QDs and Alexa 680, respectively. A control anti-CD20 antibody,
which binds only CD20 protein expressed on the surface of mature
B cells, was conjugated to Alexa 680. Size exclusion chromato-
graphy was performed to measure the molecular weights of the
conjugates. As shown in Figure 1, pure QDs and AVE-1642 QDs
have calculated molecular weights of 1170.7 and 1227.0kDa,
respectively, much larger than those of the Alexa 680 conjugates.
As Alexa 680 is a small molecule, its conjugation to antibodies did
not have a significant effect on molecular mass compared with
antibody alone.
Specific binding of AVE-1642-conjugated QDs and Alexa
680 to cells that express IGF1R in vitro
Pure unconjugated QDs, or AVE-1642-conjugated QDs, were
incubated with R cells, a mouse embryo fibroblast cell line that
has genetic deletion of the IGF1R gene. After washing with FACS
buffer, bound cell fluorescence was analysed by flow cytometry. No
specific fluorescence was detected on cell surface. When R-/IGF1R
cells, a cell line stably transfected with a human igf1r cDNA, were
incubated with pure QDs or AVE-1642 QDs, only AVE-1642 QDs
showed bound fluorescence. Pure QDs failed to bind to cell
surface. In addition, if R-/IGF1R cells were pretreated with AVE-
1642 antibody to downregulate IGF1R level, AVE-1642 QDs no
longer bound to cell surface with a diminished IGF1R level
(Figure 2A). Similar results were obtained with the AVE-1642-
conjugated Alexa 680 (Figure 2B).
The ability of AVE-1642-conjugated QDs and Alexa 680 to bind
to MCF-7 cells, a breast cancer cell line that expresses high level of
IGF1R, was also examined. As shown in Figure 2C, AVE-1642 QDs,
but not pure QDs, bound to MCF-7 cells. AVE-1642-conjugated
Alexa 680, but not Alexa 680 alone, or the anti-CD20 conjugates,
bound to MCF-7 cells. In addition, we confirmed that the anti-
CD20 Alexa 680 conjugates recognised B cells specifically by flow
cytometry (data not shown).
Therefore, our results suggest that in vitro, both AVE-1642-
conjugated QDs and Alexa 680 were able to detect IGF1R
expression and its downregulation with similar affinity.
Uptake of QD fluorescence in mice carrying xenograft
tumours
Athymic mice, 4–5 weeks old, were injected with R-/IGF1R cells
to form xenograft tumours. When tumour volumes reach
100–300mm
3, equal amounts of pure QDs, or AVE-1642 QDs
(0.1nmol), were injected into the tail vein of the mice. Blood was
drawn and the intensity of QD fluorescence was examined using
the Maestro in vivo imaging system. Quantum dot fluorescence
10 14 18 22
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Figure 1 QD conjugates had a much larger molecular weight compared
with Alexa 680 conjugated. Gel filtration samples, including AVE-1642 QDs
(AVE-QD 705), QDs, anti-CD20 Alexa 680 (aCD20-Alexa 680), anti-
CD20 antibody, AVE-1642 Alexa 680 (AVE-Alexa 680), and AVE-1642,
were fractionated with a Superdex G200 size exclusion column, eluted
with P500 buffer (0.5 M NaCl, 50mM KH2PO4,1m M EDTA, pH 7.0) and
the relative peak retention time quantitated by absorbance at 280nm.
Molecular weights of the conjugates were calculated according to a
molecular weight standards kit.
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was undetectable by fluorescence imaging (data not shown).
Therefore, whole-body in vivo imaging was performed at 2 and
24h after QD injection.
With an excitation source at 575–605nm, Maestro in vivo
imaging system was used to capture fluorescence at 10nm stepwise
from 645 to 850nm. After mixed raw images were captured,
Maestro 2.2 software was used to perform spectral unmixing and
to isolate autofluorescence and QD fluorescence. Finally, auto-
fluorescence image and QD fluorescence image were overlayed
with pseudocolours to show the localisation of QD signal in the
whole body. As shown in Figure 3A, by 2h, there was a large
amount of QD fluorescence in the liver, spleen, lymph nodes, and
bone marrow. These are all organs that contain the reticulo-
endothelial system (RES), where the phagocytic cells are present
in large quantity. In addition, the capillary beds of these organs are
all highly permeable sinusoids, with a discontinuous endothelium.
The strong nonspecific uptake obscured any tumour uptake in
the intact animal. To evaluate tumour-specific uptake, mice were
killed and xenograft tumours were removed and subjected to
ex vivo imaging. As shown in Figure 3B, tumours in mice injected
with pure QDs and AVE-1642 QDs both had small amount of
fluorescence, especially in the centre of the tumour. However,
multiple experiments showed that there was not a substantial
difference between the fluorescence of unconjugated QDs and
AVE-1642 QDs located in tumours. In addition, downregulation of
IGF1R levels by antibody pretreatment did not show a significant
difference in AVE-QD fluorescence targeting (data not shown).
Thus, QDs could localise to the tumour, but the localisation was
not specific for IGF1R expression.
To exclude the possibility that the AVE-1642 chemical linkage
with QDs was unstable in serum and resulted in the dissociation of
the antibody with QDs, we developed an alternative linkage
method to conjugate AVE-1642 with QDs. The free carboxyl
groups of any aspartic and glutamic residues in the antibody were
activated with EDC/sulpho-NHS, and then directly conjugated to
the amine group on the QDs. Theoretically, the bond between
AVE-1642 and QDs would be as stable as the peptide bond in AVE-
1642. These ‘direct-linkage AVE-1642 QDs’ bound to IGF1R-
expressing cells in vitro, and they did not affect the nonspecific
uptake or tumour targeting in vivo (data not shown).
QD cellular localisation in the liver
To detect the anatomic location of the QDs in the liver, liver
sections were stained with toluidine blue to facilitate differential
interference contrast (DIC) imaging. Overlay of QD fluorescence
and the DIC imaging of the liver showed that AVE-1642 QDs
were localised in the hepatic sinusoids at 2 and 24h post-injection,
despite the fact that the sinusoids are highly permeable
(Figure 4A). A specific antibody against MOMA-2, a cell
marker for monocytes and macrophages, showed that QD
fluorescence co-localised with MOMA-2 staining (Figure 4B),
suggesting that QDs were engulfed by Kupffer cells, the liver-
specific macrophages. Same results were obtained for the pure
QDs (data not shown).
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Figure 2 Both AVE-1642-conjugated QDs and Alexa 680 bound to cells that express IGF1R. R cells, R-/IGF1R cells, or MCF-7 cells were trypsinised,
resuspended in FACS buffer, and incubated with pure QDs, AVE-1642-conjugated QDs (AVE-QD 705) (A), AVE-1642-conjugated Alexa 680 (AVE-Alexa
680) (B), or both types of conjugates, including an anti-CD20 Alexa 680 conjugate (C) for 1h. In addition, R-/IGF1R cells were pretreated with AVE-1642
(AVE) antibody for 24h, and then incubated with AVE-QDs or AVE-Alexa 680. The fluorescence of bound QDs, or Alexa 680, was analysed by flow
cytometry. The horizontal axis of the diagram represents the fluorescent intensity, and the vertical axis shows the percentage of maximum cell number.
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depletion
It has been hypothesised that the phagocytosis by macrophages in
the RES system is a major driving force for the nonspecific hepatic
uptake (Simberg et al, 2007). To decrease the nonspecific uptake
by organs with RES system, and increase the chance of QDs to
reach tumour, we treated mice with clodronate liposomes to
temporarily deplete macrophages in the RES system. Clodronate
liposomes, once phagocytosed by macrophages, accumulate inside
the cell and cause cell apoptosis (Van Rooijen and Sanders, 1994).
However, macrophage depletion did not prevent the nonspecific
uptake, and identical imaging patterns were obtained after AVE-
1642 QDs were delivered (Figure 5A). After whole-body imaging,
mice were killed and liver sections were stained with MOMA-2, the
cell marker for macrophages. Confocal microscopy image con-
firmed that the majority of Kupffer cells had been successfully
depleted by the clodronate liposome (Figure 5B). Thus, our data
show that QDs undergo phagocytosis by Kupffer cells in liver
sinusoids; however, QD localisation to the liver is independent of
this process.
Specific tumour targeting of AVE-1642 Alexa 680
As a direct comparison, equal amounts of AVE-1642-conjugated
Alexa 680 (0.1nmol) were injected into mice carrying R-/IGF1R
xenograft tumours. Whole-body imaging was performed at 2h, 5h,
1 day, 2 days, 4 days, and 10 days time frame. Starting at day 1, we
observed specific Alexa 680 fluorescence in the xenograft tumours.
Figure 6A shows images captured after 2 days of Alexa 680
administration. The fluorescence lasted for at least 4 days and
diminished after 10 days. Uptake was not observed in any
mouse organ or tissue (Figure 6A). In addition, tumour ex vivo
imaging confirmed the Alexa 680 fluorescence at the tumour sites
(Figure 6B). Imaging of the organs in the chest and abdominal
region of the mice reveals no Alexa 680 fluorescence (data not
shown).
To exclude the possibility that Alexa 680 by itself may target to
tumours, equal amounts of AVE-1642-conjugated Alexa 680 or
anti-CD20-conjugated Alexa 680 were injected into mice carrying
MCF-7 xenograft tumours. Whole-body imaging was performed
after 2 days. As shown in Figure 6C, only AVE-1642-conjugated
A
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Figure 3 QD fluorescence was mainly localised to the liver, spleen,
lymph nodes, and bone marrow, with small amount of tumour targeting.
(A) Mice carrying R-/IGF1R xenograft tumours in the left (no. 2) mammary
fat pad were injected with PBS solution (C), 0.1nmol of QDs (Q), or AVE-
1642 QDs (AQ) through tail vein. Mice were imaged after 2h using the
Maestro in vivo imaging system. (a) Mixed raw signal captured by Maestro.
(b) Autofluorescence after spectral unmixing. (c) QD 705nm fluorescence
after spectral unmixing. (d) Pseudocoloured overlay, with autofluorescence
as white colour and QD fluorescence as red colour. (B) Mice were killed
and tumours were removed. Tumour ex vivo imaging was performed using
the Maestro system.
QD 705
DAPI MOMA-2
QD 705 Overlay
DIC Overlay
24 h
2 h
A
B
Figure 4 QDs were localised to the hepatic sinusoids and engulfed by
Kupffer cells. (A) After AVE-1642 QDs were delivered systematically for
2h (top panel) or 24h (bottom panel), mice were killed and liver pieces
were frozen in OCT solution. Liver sections were stained with toluidine
blue and imaged by confocal microscopy. QD 705 fluorescence is shown in
the left, DIC image is shown in the middle, and an overlay image is shown in
the right. The scale bar in the image is 20mm. (B) Liver sections with AVE-
1642 QDs delivered for 2h were stained with anti-MOMA-2 antibody,
followed by an Alexa 488-conjugated secondary antibody. Finally, the
sections were stained for the nucleus with DAPI. Confocal microscopy was
performed to examine the localisation of QD fluorescence in the liver
tissue. The scale bar in the image is 20mm.
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failed to accumulate specifically in mouse body. Tumour ex vivo
imaging confirmed the in vivo results at the tumour sites
(Figure 6D).
Detection of IGF1R downregulation in xenograft tumours
by AVE-1642 Alexa 680
Next, we studied whether AVE-1642-conjugated Alexa 680 target-
ing to tumours was dependent on IGF1R expression. Mice carrying
R-/IGF1R tumours were pretreated with AVE-1642 antibody for 2
days before the injection of AVE-1642-conjugated Alexa 680,
which efficiently downregulates IGF1R levels in tumours (Sachdev
et al, 2006). As shown in Figure 7, the tumours with diminished
IGF1R levels showed a dramatically decreased fluorescence,
compared with the tumours with a regular amount of IGF1R level.
Therefore, our data suggest that AVE-1642-conjugated Alexa 680
can identify IGF1R expression and its downregulation in tumour
xenograft models.
DISCUSSION
Anatomic imaging is commonly used to gauge the efficacy of
cancer therapy. However, current in vivo imaging techniques,
including X-ray, computerised axial tomography, ultrasound,
nuclear imaging, and magnetic resonance imaging, do not have
the ability to detect specific cancer cell proteins that serve as
molecular targets. Investigational studies utilising positron emis-
sion tomography and scintigraphy have shown that it is possible to
detect HER2 and ER in vivo (Linden et al, 2006; Perik et al, 2006),
and an increased need to visualise these tumour targets is apparent
as targeted therapies against specific molecules in cancer are
rapidly developing.
Given the critical role of IGF1R in cancer biology, many new
anti-IGF1R drugs have been developed, including monoclonal
antibodies and tyrosine kinase inhibitors. Several monoclonal
antibodies have shown early promise in clinical trials. However, an
in vivo imaging technique, to identify appropriate patients for
anti-IGF1R therapy, and to track the delivery of such a therapy, is
not available. Therefore, there is an important clinical need to
develop in vivo imaging techniques to detect and measure the level
of the molecules in vivo non-invasively. Owing to the high
brightness of QDs, they have been studied extensively for their
application in cancer imaging. However, through direct compa-
rison, our data have shown that small-molecule fluorophores,
conjugated with monoclonal antibodies, are more suitable to
detect IGF1R-expressing tumours in vivo through non-invasive
fluorescent imaging.
Our data have shown that both AVE-1642-conjugated QDs and
Alexa 680 bind specifically to IGF1R-expressing cells. Furthermore,
they both detect the downregulation of IGF1R after treatment with
a monoclonal antibody. Direct conjugation of AVE-1642 with QDs
or Alexa 680 does not alter the ability of AVE-1642 to bind IGF1R.
These data suggest that both agents could be used clinically in vitro
to examine the IGF1R level in primary tumours. As the
fluorescence intensity correlates with IGF1R level, antibody-
conjugated fluorophores can be used to quantitatively measure
IGF1R levels by flow cytometry.
In the past few years, QDs, especially the Cd/Te QDs with
emission wavelengths at near-infrared region, have been studied
intensively for cancer imaging. Several groups have shown that
after systematic administration, antibody- or ligand-conjugated
QDs can localise to tumour (Gao et al, 2004; Cai et al, 2006; Tada
et al, 2007; Diagaradjane et al, 2008). However, it was not clear how
efficient conjugated QDs can reach and bind specific receptors on
tumour cells after intravenous delivery in vivo. Recently, Cai et al
(2006) have shown that RGD (Arg-Gly-Asp) peptide-conjugated
QDs that specifically recognise avb3 integrin localised to tumour
with a heterogeneous pattern. At the microscopic level, they
discovered that QDs were retained in the tumour vasculature and
did not appear to contact the tumour cells (Cai et al, 2006).
Diagaradjane et al (2008) also found that an EGF-conjugated QD
bound to EGFR in tumour vasculature after systematic delivery.
Consistent with their data, in our studies, both pure QDs and AVE-
1642-conjugated QDs were localised to tumours with a hetero-
geneous pattern, suggesting that they localised to tumour
vasculature. As AVE-1642 antibody specifically binds human
IGF1R and does not bind to mouse IGF1R, the staining pattern
we saw was not due to detection of murine IGF1R on endothelial
cells.
It has been a consistent observation that systemic administra-
tion of pure, non-targeted QDs, and cell-targeted QDs, accumu-
lates in substantial quantities in the liver, spleen, lymph nodes, and
bone marrow in animal model systems (Ballou et al, 2004, 2007;
Gao et al, 2004; Cai et al, 2006; Jackson et al, 2007; Diagaradjane
et al, 2008; Li and Huang, 2008). These organs all contain the RES
system, where macrophage cells reside. We have shown that QDs
or conjugated QDs accumulated inside the sinusoids in the liver
PBS
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Control liposome treated
DAPI MOMA-2
QD 705 Overlay
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QD 705 Overlay
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Figure 5 Depletion of macrophages failed to decrease nonspecific
uptake. (A) Mice carrying R-/IGF1R xenograft tumours were administered
with PBS or clodronate liposome. After 24h, mice were tail vein injected
with 0.1nmol of AVE-1642 QDs. Two hours later, whole-body imaging
was performed with the Maestro in vivo imaging system. (a) Mixed raw
signal captured by Maestro. (b) Autofluorescence after spectral unmixing.
(c) QD 705nm fluorescence after spectral unmixing. (d) Pseudocoloured
overlay with autofluorescence as white colour and QD fluorescence as red
colour. (B) After whole-body imaging, mice were killed and liver sections
were stained for MOMA-2. Confocal microscopy was performed to
examine the presence or absence of MOMA-2.
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sand were subsequently phagocytosed by Kupffer cells. Our data
were consistent with others’ findings that QDs in the liver tend
to be engulfed by macrophages (Jackson et al, 2007). However,
when we deliberately depleted macrophages by clodronate
liposomes, we still observed that QDs accumulated in the RES-
containing organs with similar kinetics. Therefore, macrophage
engulfing was not the proximal cause of preferential localisation.
What causes the localisation to RES-containing organs is unclear.
It is noteworthy that virtually all nano-size crystals, including
nano-sized liposomes (Li and Huang, 2008), QDs (Zhang et al,
2008b), and iron oxide nanocrystals (Simberg et al, 2007), tend to
accumulate in these RES-containing organs. Therefore, it is likely
that the size of these particles has a critical role in the nonspecific
uptake. A recent study suggests that smaller QDs (with a size less
than 5.5nm), but not large QDs, could be cleared through renal
excretion (Choi et al, 2007). However, small-size QDs normally
have short emission wavelengths, which are not suitable for in vivo
imaging. Quantum dots with longer emission wavelengths may be
retained in the body for at least 2 years and remain fluorescent
(Ballou et al, 2007). This nonspecific uptake will certainly hinder
the application of QDs in clinical settings. Even if the tumour
uptake was specific, the long-term consequences of QDs in the
liver would need to be understood before clinical applications
could proceed.
Beyond this concern about the nonspecific uptake in the
RES-containing organs, our data show that QD-conjugated
antibodies were unable to specifically localise to tumours. Thus,
this approach would not be suitable for in vivo imaging to target
molecules on tumour surface. Although QD-conjugated antibodies
performed well in vitro, there are certainly less complicated ways
Control
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Figure 6 AVE-1642 Alexa 680 solely targeted to tumours that express IGF1R. (A) Mice carrying R-/IGF1R xenograft tumours were injected through tail
vein with either PBS or 0.1nmol of AVE-1642 Alexa 680 (AVE-Alexa 680). Imaging was taken 48h later. (a) Mixed raw signal captured by Maestro. (b)
Autofluorescence after spectral unmixing. (c) Alexa 680 fluorescence after spectral unmixing. (d) Pseudocoloured overlay with autofluorescence as white
colour and Alexa 680 fluorescence as red colour. (B) After in vivo imaging, mice were killed. Tumour ex vivo images were taken using the Maestro system.
(C) Mice carrying MCF-7 xenograft tumours were injected through tail vein with either anti-CD20 Alexa 680 (aCD20) or AVE-1642 Alexa 680 (AVE).
Imaging was taken 48h later. (D) After in vivo imaging, mice were killed. Tumour ex vivo images were taken using the Maestro system.
Mixed signal Autofluorescence
Alexa 680 Pseudocoloured overlay
Control AVE pretreated
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Figure 7 AVE-1642 Alexa 680 detected IGF1R downregulation. Mice
carrying R-/IGF1R xenograft tumours were treated with or without 200mg
of AVE-1642 antibody. Two days later, mice were injected through tail vein
with 0.1nmol of AVE-1642 Alexa 680. Mice whole-body imaging was taken
24h later. (A) Mixed raw signal captured by Maestro. (B) Autofluores-
cence after spectral unmixing. (C) Alexa 680 fluorescence after spectral
unmixing. (D) Pseudocoloured overlay with autofluorescence as white
colour and Alexa 680 fluorescence as red colour.
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sto measure cell-surface receptor expression in tumours removed
from the body.
In contrast, small-molecule fluorophores, such as Alexa 680,
coupled with AVE-1642 had the ability to identify IGF1R
expression in vivo. As the size of Alexa 680 is much smaller than
that of the antibody, it seemed that the pharmacodynamics of
AVE-1642 conjugated to Alexa 680 is similar to that of the
antibody alone. Without nonspecific uptake in the RES-containing
organs, AVE-1642 Alexa 680 circulated long enough to accumulate
in the xenograft tumour. In addition, previous studies in our lab
have shown that AVE-1642 targeted to tumour and downregulate
IGF1R levels in tumour after intraperitoneal injection. AVE-1642
Alexa 680 could monitor this downregulation of IGF1R by
diminished tumour fluorescence. As downregulation of IGF1R
was associated with decreased tumour growth (Burtrum et al, 2003;
Maloney et al, 2003; Goetsch et al, 2005), AVE-1642 Alexa 680
could be used to predict response post-therapy by fluorescent
imaging. We also realise that our study utilised optimal conditions
as AVE-1642 does not bind mouse IGF1R; therefore, the potential
background generated by mouse IGF1R was avoided. It is
important in future studies to include anti-IGF1R antibodies, such
as A12 (Wu et al, 2005; Rowinsky et al, 2007), which recognise
both human and mouse IGF1R, to examine the tumour-to-
background signal ratio from regions of interest in tumour and
normal tissue.
In summary, our data, coupled with others’ finding, suggest that
imaging particles at nano-size tend to have nonspecific uptake,
either alone or conjugated with antibody. In contrast, small-
molecule probes conjugated to antibody are more specific and are
able to reach tumour sites. On the basis of these characteristics, we
anticipate that antibody-conjugated small-molecule probes will
be able to localise to metastasised tissue in the lymph nodes and
distant organs. A recent progress indicated that small-molecule
fluorescent imaging was successfully applied clinically to aid
glioma surgery (Stummer et al, 2006). Therefore, it is feasible
to use antibody-conjugated small-molecule fluorophores to
identify tumour cells in vivo. This technology could aid in several
surgical procedures, but more importantly, it could be used to
non-invasively characterise biological properties of tumour cells.
Currently, small-molecule fluorophores have relatively lower
extinction efficiency than QDs, which limits their applications in
deep-tissue imaging to detect metastasis. However, this is a very
active research area and we anticipate breakthroughs to generate
brighter small-molecule fluorophores in the near future to fulfil
this gap.
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